2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™

BACKGROUND: Telavancin (TLV) is a lipoglycopeptide antibacterial active against a wide range of Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus. Infections due to S. aureus with elevated vancomycin (VAN) minimum inhibitory concentrations (MIC) are associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Micah, Nwaigwe, Casmiar, Clay, Candice, Barnes, Chris, Castaneda-Ruiz, Bibiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255514/
http://dx.doi.org/10.1093/ofid/ofy210.2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255514/
http://dx.doi.org/10.1093/ofid/ofy210.2022

Ejemplares similares